

Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

<https://marketpublishers.com/r/EDF7BD5EF672EN.html>

Date: April 2023

Pages: 86

Price: US\$ 4,400.00 (Single User License)

ID: EDF7BD5EF672EN

Abstracts

Europe soft tissue sarcoma market is expected to grow at a significant rate during the forecast period, 2024-2028. The rise in the incidence and prevalence of different types of cancers coupled with the increasing research & development (R&D) activities are anticipated to bolster the growth of the market. The rising number of people suffering from soft tissue sarcoma in the region is augmenting the growth of the market. The advent of advanced therapies, such as targeted and biological, is also a contributing factor. There is a growing focus on personalized medicine along with huge investment in anti-cancer treatment research, which is likely to discover new paths for Europe soft tissue sarcoma treatment market in the coming future. Furthermore, there is an increase in the number of clinical trials going on in the region, which is facilitating the growth of the market. Rising ease in FDA approvals as well as the patent expiry of branded drugs, are some of the factors fuelling the growth of the market.

Soft tissue sarcoma is a rare type of cancer that develops in soft tissues of the human body, such as fat, muscle, nerves, fibrous tissues, or deep skin tissues. About 40 percent of the cases occur in the legs, usually at or above the knee. Fifteen percent develop in the hands and arms, another 15 percent in the head and neck, and the remaining 30 percent in the shoulders, chest, abdomen, or hips. Moreover, it is not classified as a tumour but can be life-threatening if cancer spreads in the human body.

Increasing Prevalence of Different Types of Cancers

Growing occurrences of various types of cancer, which start in soft tissues such as tendons, fat, nerves, blood vessels, and others, are expected to propel the growth of the market. There is a rise in the number of cases of sarcoma, which is augmenting the growth of the market. According to cancer research UK, there are about 4,300 new soft tissue sarcoma cases in England every year, which is around 12 every day. The elderly population is more at risk as they can develop soft tissue sarcoma cancer. Around 40 in 100 soft tissue sarcomas (40%) are diagnosed in individuals aged 65 or above.

Increasing Research & Development (R&D) Activities

There is a rise in the number of research activities on drugs and other therapies, which is likely to bolster the growth of the market. Researchers are focusing on second-line therapies for patients who relapse or are refractory, as there are no approved therapies for the same. Heavy funding by the government, as well as the private sector for R&D purposes, is facilitating the growth of the market.

Rise in the Number of Clinical Trials

There is a large number of clinical studies which are going on for soft tissue sarcoma in the region, which is projected to bolster the growth of the market. There are a total of 578 clinical studies in Europe, out of which 242 studies are completed. For instance, in 2021, a clinical trial for the “NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms with Soft Tissue Sarcoma of the Extremity and Trunk Wall” was completed.

Market Segmentation

Europe soft tissue sarcoma market is segmented into treatment, disease type, end user, company, and country. Based on treatment, the market is divided into targeted therapy, chemotherapy, anti-angiogenesis drug, and radiation therapy. Based on disease type, the market is categorized into local sarcoma, regional sarcoma, and metastatic sarcoma. Based on end users, the market is bifurcated into hospitals & clinics, ambulatory surgical centers, and others. In terms of countries, the market is categorized into Germany, France, United Kingdom, Italy, Spain, Netherlands, Belgium, Sweden, Poland, and Greece.

Market Players

GlaxoSmithKline PLC, Eli Lilly Italia - S.p.A., Pfizer Deutschland GmbH., Bristol-Myers Squibb SARL, F. Hoffmann-La Roche AG, Teva Pharmaceuticals Europe BV, Celgene Europe Ltd, Zimmer GmbH, RTI UK Ltd, and Integra LifeSciences Services France SASU, are some of the leading companies in the market.

Report Scope:

In this report, Europe soft tissue sarcoma market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Europe Soft Tissue Sarcoma Market, By Treatment:

Targeted Therapy

Chemotherapy

Anti-Angiogenesis Drug

Radiation Therapy

Europe Soft Tissue Sarcoma Market, By Disease Type:

Local Sarcoma

Regional Sarcoma

Metastatic Sarcoma

Europe Soft Tissue Sarcoma Market, By End User:

Hospitals & Clinics

Ambulatory Surgical Centers

Others

Europe Soft Tissue Sarcoma Market, By Country:

France

Germany

United Kingdom

Italy

Spain

Belgium

Netherlands

Sweden

Poland

Greece

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Europe soft tissue sarcoma market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiat...

Profit margin analysis in the case of the direct and indirect sales channels.

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. EUROPE SOFT TISSUE SARCOMA MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy)
 - 5.2.2. By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma)
 - 5.2.3. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)

- 5.2.4. By Country
- 5.2.5. By Company (2022)
- 5.3. Market Map
 - 5.3.1. By Treatment
 - 5.3.2. By Disease Type
 - 5.3.3. By End User
 - 5.3.4. By Country
- 5.4. Europe: Country Analysis
 - 5.4.1. Germany Humanized Mice Model Market Outlook
 - 5.4.1.1. Market Size & Forecast
 - 5.4.1.1.1. By Value
 - 5.4.1.2. Market Share & Forecast
 - 5.4.1.2.1. By Treatment
 - 5.4.1.2.2. By Disease Type
 - 5.4.1.2.3. By End User
 - 5.4.2. France Humanized Mice Model Market Outlook
 - 5.4.2.1. Market Size & Forecast
 - 5.4.2.1.1. By Value
 - 5.4.2.2. Market Share & Forecast
 - 5.4.2.2.1. By Treatment
 - 5.4.2.2.2. By Disease Type
 - 5.4.2.2.3. By End User
 - 5.4.3. United Kingdom Humanized Mice Model Market Outlook
 - 5.4.3.1. Market Size & Forecast
 - 5.4.3.1.1. By Value
 - 5.4.3.2. Market Share & Forecast
 - 5.4.3.2.1. By Treatment
 - 5.4.3.2.2. By Disease Type
 - 5.4.3.2.3. By End User
 - 5.4.4. Italy Humanized Mice Model Market Outlook
 - 5.4.4.1. Market Size & Forecast
 - 5.4.4.1.1. By Value
 - 5.4.4.2. Market Share & Forecast
 - 5.4.4.2.1. By Treatment
 - 5.4.4.2.2. By Disease Type
 - 5.4.4.2.3. By End User
 - 5.4.5. Spain Humanized Mice Model Market Outlook
 - 5.4.5.1. Market Size & Forecast
 - 5.4.5.1.1. By Value

- 5.4.5.2. Market Share & Forecast
 - 5.4.5.2.1. By Treatment
 - 5.4.5.2.2. By Disease Type
 - 5.4.5.2.3. By End User
- 5.4.6. Netherlands Humanized Mice Model Market Outlook
 - 5.4.6.1. Market Size & Forecast
 - 5.4.6.1.1. By Value
 - 5.4.6.2. Market Share & Forecast
 - 5.4.6.2.1. By Treatment
 - 5.4.6.2.2. By Disease Type
 - 5.4.6.2.3. By End User
- 5.4.7. Belgium Humanized Mice Model Market Outlook
 - 5.4.7.1. Market Size & Forecast
 - 5.4.7.1.1. By Value
 - 5.4.7.2. Market Share & Forecast
 - 5.4.7.2.1. By Treatment
 - 5.4.7.2.2. By Disease Type
 - 5.4.7.2.3. By End User
- 5.4.8. Sweden Humanized Mice Model Market Outlook
 - 5.4.8.1. Market Size & Forecast
 - 5.4.8.1.1. By Value
 - 5.4.8.2. Market Share & Forecast
 - 5.4.8.2.1. By Treatment
 - 5.4.8.2.2. By Disease Type
 - 5.4.8.2.3. By End User
- 5.4.9. Poland Humanized Mice Model Market Outlook
 - 5.4.9.1. Market Size & Forecast
 - 5.4.9.1.1. By Value
 - 5.4.9.2. Market Share & Forecast
 - 5.4.9.2.1. By Treatment
 - 5.4.9.2.2. By Disease Type
 - 5.4.9.2.3. By End User
- 5.4.10. Greece Humanized Mice Model Market Outlook
 - 5.4.10.1. Market Size & Forecast
 - 5.4.10.1.1. By Value
 - 5.4.10.2. Market Share & Forecast
 - 5.4.10.2.1. By Treatment
 - 5.4.10.2.2. By Disease Type
 - 5.4.10.2.3. By End User

6. MARKET DYNAMICS

- 6.1. Drivers
- 6.2. Challenges

7. PRICING ANALYSIS

8. MARKET TRENDS & DEVELOPMENTS

9. COMPETITIVE LANDSCAPE

- 9.1. Competition Outlook
- 9.2. Regional Players Profiled (Leading Companies)
 - 9.2.1. GlaxoSmithKline PLC
 - 9.2.2. Eli Lilly Italia - S.P.A.
 - 9.2.3. Pfizer Deutschland GmbH.
 - 9.2.4. Bristol-Myers Squibb SARL
 - 9.2.5. F. Hoffmann-La Roche AG
 - 9.2.6. Teva Pharmaceuticals Europe BV
 - 9.2.7. Celgene Europe Ltd
 - 9.2.8. Zimmer GmbH
 - 9.2.9. RTI UK Ltd
 - 9.2.10. Integra LifeSciences Services France SASU

10. STRATEGIC RECOMMENDATIONS

I would like to order

Product name: Europe Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Country, Competition, Forecast & Opportunities, 2028

Product link: <https://marketpublishers.com/r/EDF7BD5EF672EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EDF7BD5EF672EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970